Structure Therapeutics' oral small molecule GLP-1, GSBR-1290, has shown promising results in Phase 1b studies, surpassing competitor benchmarks for weight loss. GSBR-1290 demonstrated potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results